Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.
Start | Author Index

651.O4.8 Molecular Pathology of Myeloma

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
2005-2007-2018-2020 - West (Moscone Center)
Moderators:
Helena Jernberg-Wiklund, PhD and Karin Vanderkerken
7:00 AM
840
CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs)

Yu-Tzu Tai, PhD1, Ender Soydan2*, Mariateresa Fulciniti2*, Weihua Song2*, Xian-Feng Li2*, Peter Burger2*, Fangxin Hong2*, Giovanni Tonon2*, Kihyun Kim2*, Mathew J. Rumizen2*, Sabikun Nahar2*, Klaus Podar2*, Dharminder Chauhan2*, Teru Hideshima2*, Daniel R. Carrasco2*, Nikhil C Munshi2*, Daniel Afar, PhD3 and Kenneth C. Anderson2*

1Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
2Dana-Farber Cancer Inst., Boston, MA
3Research, PDL BioPharma, Inc., Redwood City, CA
7:15 AM
841
Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma

Yang Yang1, Joseph P. Ritchie1*, Larry J. Suva2* and Ralph D. Sanderson1*

1Department of Pathology, Center for Metabolic Bone Disease and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
2Dept of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Liitle Rock, AR
7:30 AM
842
CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Ping Zhou, MD, PhD1, Adam M Boruchov, MD2*, James E. Hoffman, MD3, Qianxing Mo4*, Adam Olshen5*, Evan Glasner2*, Ezio Bonvini6*, Scott Koenig6*, Ellen Drieghe2*, Martin Fleisher, PhD7*, Peter Maslak, MD8, Hani Hassoun, MD9, Adam D Cohen, MD2, Heather Landau, MD10, James W. Young, MD11, Suresh C Jhanwar, PhD10*, Stephen D Nimer, MD2* and Raymond L Comenzo12

1Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Bronx, NY
2Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
3Education and Training, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
4Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
5Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New City, NY
6MacroGenics, Inc, Rockville, MD
7Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY
8Memorial Sloan-Kettering Cancer Ctr., New York, NY
9Memorial Sloan-Kettering Cancer Center, New York, NY
10Memorial Sloan Kettering Cancer Ctr., New York, NY
11Adult Allogeneic Bone Marrow Transplantation, Memorial Sloan-Kettering Cancer Ctr., New York, NY
12Hematology Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
7:45 AM
843
The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth In Vitro and In Vivo and Enhances the Anti-MM Effects of Melphalan

Eric Sanchez1*, Richard A Campbell, BS1*, Jeffrey A Steinberg1*, Mingjie Li1*, Haiming Chen, MD, PhD1*, Benjamin Bonavida, PhD2 and James R. Berenson, MD1

1Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
8:00 AM
844
The EphrinB2/EphB4 Axis Is Dysregulated in Osteoprogenitors from Myeloma Patients and Its Activation by EphrinB2-Fc or EhpB4-Fc Affects Myeloma Bone Disease and Tumor Growth in Vivo

Angela Pennisi*, Wen Ling*, Xin Li*, Jianmei Chen*, Sharmin Khan* and Shmuel Yaccoby

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
8:15 AM
845
Immunomodulatory Derivatives of Thalidomide (IMiD)-Induced Neutropenia Is Associated with PU.1 Downregulation and Myeloid Maturation Arrest

Rekha Pal1*, G. David Roodman, MD, PhD2, Markus Mapara, MD, PD3, Lynn Mocsinski, MD4*, Alan F List, MD4* and Suzanne Lentzsch, MD, PhD5

1Hematology/Oncology, Hillman Cancer Centre, Pittsburgh, PA
2University of Pittsburgh, VA Pittsburgh Healthcare System (646) and the University of Pittsburgh, Pittsburgh, PA
3Research Pavilion, Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA
4Division of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
5UPMC Cancer Pavilion, Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA
8:30 AM
846
Bortezomib Induces Osteoblast Differentiation Via Wnt-Independent Activation of Beta-catenin/TCF Signaling

Ya-wei Qiang*, Bo Hu*, Yu Chen*, Ying Zhong*, Bart Barlogie and John D. Shaughnessy Jr., PhD

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
8:45 AM
847
Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Richard J Rickles, Ph.D.1*, Laura Pierce1*, Thomas Giordano1*, Winnie F. Tam, Ph.D.1*, Douglas W. McMillin, BSc, PhD2*, Kenneth C. Anderson, MD2, Constantine Mitsiades, M.D., Ph.D.2 and Margaret S Lee, Ph.D.1*

1CombinatoRx, Incorporated, Cambridge, MA
2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH